



| Please attach the following documents with this test order | | |
|--|--|--|
| ☐ Medical Necessity ☐ SOAP Notes ☐ Visit History Notes | ☐ Patient Care-plan ☐ Medication List, if any | |

| URINE TOXICOLOGY TEST REQUISITION FORM - SCREENING AND CONFIRMATION |
|---|
| |

| PATIENT INFORMATION | | | | | | | | |
|---|--|---|--|---|--|---|--|--|
| Patient First Name | | Patient Last Name | | | Biological Sex 🔲 F 🔲 M | | | |
| Date of Birth (MM/DD/YYYY) | Phone Number | r En | | mail | Social S | | ecurity Number | |
| Address | <u> </u> | City | | | State | | Zip | |
| Ethnicity: African American Asian Caucasian Hispanic Jewish(Ashkenazi) Portuguese Other | | | | | | | | |
| PATIENT INSUR | ANCE INFORMATION | | SPE | CIME | N AND P | PRACTICE IN | FORMATION | |
| ☐ Insurance ☐ Self-Pay ☐ Name of the insurance | Client Bill Secondary Insurance, If any | / | Collected B | Зу: | PRACTIC | E INFORMATI | ON | |
| Insurance Policy/ID number | Name of the insured | | | Practice/Facility Name: | | | | |
| Insurance Group number | Date of Birth of Insured | | Phone: | | | Fax: | | |
| | | TES | T PANEL | | | | | |
| ☐ Clinical Drug Screening ☐ Confirmation ☐ Screening and Confirmation ☐ Urine Heavy Metals ☐ (Hg, Pb, As, Cd) | | | | | | | | |
| Clinical Drug Screen 9001 Screen Panel 901 Amphetamines 902 Barbiturates 903 Benzodiazapines | 904 Buprenorphine 905 Cocaine Metabolites 906 Ethanol 907 Methadone | | 908 Opiates 909 Cannabino 911 Ecstasy | ids | | 9003 Validity T 912 Specific C 914 pH 915 Urine Cre | Gravity | |
| POC Results + - AMP | 610 Amphetamine Sleep 612 Methylphenidate 650 614 Phentermine 649 6551 6008 Amphetamines 635 611 Methamphetamine 652 653 6002 Benzodiazepines 654 615 7-Aminoclonazepam 669 619 Nordiazepam 620 Oxazepam 6005 621 Temazepam 655 622 Lorazepam 658 617 Alpha Hydroxyalprazolam 656 6606 | Muscoing Aid Carists Gabay Ketam Norke Mepri Prega Zolpic Cyclol Barbit Butall Phenco Pento | orodol pentin pinne tamine pbamate balin lem penzaprine urates | 625 Co 626 M· 627 Hy 630 Ox 632 Ox 638 M· 639 No 6007 Illio 662 6-/ 663 Be 664 M· 665 M· 666 Ph | deine orphine drocodone dromorphone ycodone ymorphone eperidine ormeperidine cits/Others: Acetyl-Morphi nzoylecgonine DA DMA encyclidine (Pr | 633 634 636 637 640 641 642 645 647 ne 6011 | Opiods Buprenorphine Norbupenorphine Fentanyl Norfentanyl Methadone EDDP Tapentadol Tramadol O-Desmethyltramadol Alcohol Ethanol (EtS) | |
| DIAGNOSIS (ICD-10) CODES Select or write-in one or more codes from the spaces/selections below (REQUIRED) | | | | | | | | |
| E87.21 - Acute metabolic acido: | sis | | F20.2 - Catator | nic schizo | phrenia | | | |

| ☐ E87.21 - Acute metabolic acidosis | ☐ F20.2 - Catatonic schizophrenia |
|--|---|
| ☐ E87.22- Chronic metabolic acidosis | ☐ F20.89 - Other schizophrenia |
| ☐ E87.29 - Other acidosis | ☐ F55.3 - Abuse of steroids or hormones |
| ☐ F10.120 - Alcohol abuse with intoxication, uncomplicated | ☐ F55.4 - Abuse of vitamins |
| ☐ F11.20 - Opioid dependence, uncomplicated | ☐ F55.8 - Abuse of other non-psychoactive substances |
| ☐ F12.120 - Cannabis abuse with intoxication, uncomplicated | ☐ F13.120 - Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicat |
| ☐ F12.220 - Cannabis dependence with intoxication, uncomplicated | ☐ F14.120 - Cocaine abuse with intoxication, uncomplicated |
| ☐ F19.20 - ther psychoactive substance dependence, uncomplicated | ☐ F14.220 - Cocaine dependence with intoxication, uncomplicated |
| ☐ F20.0 - Paranoid schizophrenia | ☐ F16.120 - Hallucinogen abuse with intoxication, uncomplicated |
| ☐ F20.1 - Disorganized schizophrenia | ☐ F18.10 - Inhalant abuse, uncomplicated |
| | |

| DIAGNOSIS (ICD-10) | CODES (Continued) | | | |
|--|---|--|--|--|
| F18.120 - Inhalant abuse with intoxication, uncomplicated F18.90 - nhalant use, unspecified, uncomplicated G40.301 - Generalized idiopathic epilepsy and epileptic syndromes, not intractable, with sta G40.309 - Generalized idiopathic epilepsy and epileptic syndromes, not intractable, with sta G40.311 - Generalized idiopathic epilepsy and epileptic syndromes, intractable, with statu G40.311 - Generalized idiopathic epilepsy and epileptic syndromes, intractable, with statu G40.319 - Generalized idiopathic epilepsy and epileptic syndromes, intractable, without stat G40.901 - Epilepsy, unspecified, not intractable, with status epilepticus G40.909 - Epilepsy, unspecified, not intractable, without status epilepticus G40.911 - Epilepsy, unspecified, intractable, without status epilepticus G40.911 - Epilepsy, unspecified, intractable, without status epilepticus G40.911 - Epilepsy, unspecified, intractable, without status epilepticus H44.0 - Atrioventricular block, first degree H44.1 - Atrioventricular block, second degree H44.1 - Atrioventricular block, second degree H47.1 - Supraventricular tachycardia H47.2 - Forsades de pointes H47.2 - Other ventricular tachycardia H47.2 - Other ventricular tachycardia M25.50 - Pain in unspecified joint M47.811 - Spondylosis without myelopathy or radiculopathy, occipito-atlanto-axial r M47.813 - Spondylosis without myelopathy or radiculopathy, lumbar region M47.813 - Spondylosis without myelopathy or radiculopathy, lumbar region M47.815 - Intervertebral disc disorders with radiculopathy, lumbosacral regio M51.15 - Intervertebral disc disorders with radiculopathy, thoracic region M51.15 - Intervertebral disc disorders with radiculopathy, lumbosacral region M51.16 - Radiculopathy, thoracic region M51.17 - New intervertebral disc degeneration, lumbar region M51.16 - Radiculopathy, thoracic region M54.11 - Radiculopathy, thoracic region M54.11 - Radiculopathy, thoracic region M54.11 - Radiculopathy, lumbar region | M60.811 - Other myositis, right shoulder M60.812 - Other myositis, left shoulder M60.821 - Other myositis, left upper arm M60.822 - Other myositis, left upper arm M60.822 - Other myositis, left upper arm M60.831 - Other myositis, left forearm M60.831 - Other myositis, left forearm M60.841 - Other myositis, left hand M60.841 - Other myositis, left hand M60.851 - Other myositis, left thigh M60.852 - Other myositis, left thigh M60.852 - Other myositis, left thigh M60.852 - Other myositis, left lower leg M60.871 - Other myositis, left ankle and foot M60.872 - Other myositis, left ankle and foot M60.872 - Other myositis, left ankle and foot M60.872 - Other myositis, unstillate and foot M60.89 - Other myositis, multiple sites M79.11 - Myalgia of mastication muscle M79.12 - Myalgia of auxiliary muscles, head and neck M79.12 - Myalgia of auxiliary muscles, head and neck M79.13 - Myalgia, other site M79.2 - Neuralgia and neuritis, unspecified M79.7 - Fibromyalgia R40.0 - Somnolence R40.1 - Stupor R41.0 - Disorientation, unspecified R41.82 - Altered mental status, unspecified R44.3 - Hallucinations, unspecified R56.9 - Unspecified convulsions Z71.51 - Drug abuse counseling and surveillance of drug abuser Z79.899 - Other long term (current) drug therapy Z91.120 - Patient's intentional underdosing of medication regimen due to financial Z91.128 - Patient's intentional underdosing of medication regimen due to age-relate Z91.138 - Patient's unintentional underdosing of medication regimen for other rea | | | |
| ☐ M54.2 - Cervicalgia | ☐ Z91.190 - Patient's noncompliance with other medical treatment and | | | |
| ☐ M54.50- Low back pain, unspecified ☐ M54.51 - Vertebrogenic low back pain | regimen due to finan Z91.198 - Patient's noncompliance with other medical treatment and | | | |
| M54.59 - Other low back pain | regimen for othe | | | |
| Additional ICD10 codes: | | | | |
| PATIENT CONSENT | | | | |
| I hereby assign all rights and benefits under my health plan and all rights and obligations that I and my dependents have under my health plan to ImmunoGenomics its assigned affiliates and authorized representatives for laboratory services furnished to me by ImmunoGenomics I irrevocably designate, authorize and appoint ImmunoGenomics or its assigned affiliates and their authorized representatives as my true and lawful attorney-in-fact for the purpose of submitting my claims, obtain a copy of my health plan document, Summary Plan Description, disclosure, appeal, litigation or other remedies in accordance with the benefits and rights under my health plan and in accordance with federal or state laws. If my health plan fails to abide by my authorization and makes payment directly to me, I agree to endorse the insurance check and forward it to Elite Clinical Laboratory immediately upon receipt. I hereby authorize ImmunoGenomics its assigned affiliates and authorized representatives to contact me or my health Plan/administrator for billing or payment purposes by phone, text message, or email with the contact information that I have provided to ImmunoGenomics, in compliance with federal and state laws. ImmunoGenomics, its assigned affiliates and their authorized representatives my release to my health plan administrator, my employer, and my authorized representative my personal health information for the purpose of procuring payment of ImmunoGenomics and for all the laboratory services. I understand the acceptance of insurance does not relieve me from any responsibility concerning payment for laboratory services and that I am financially responsible for all charges whether or not they are covered by my insurance. | | | | |
| Signature of Patient or Patient Representative / Relationship to Patient | Date: | | | |
| PHYSICIAN CONSENT | | | | |
| As part of my antibiotic stewardship policy, I find it medically necessary to rapidly determine and differentiate a viral and/or bacterial infection in order to treat with or | | | | |
| | | | | |

without appropriate antibiotics. Having the most accurate and timely data available to me directly guides my treatment and patient management. Empiric treatment and management leads to inappropriate and unnecessary antibiotic use (50% according to the CDC) and delayed diagnosis which can lead to severe consequences. Standard antibody/antigen detection is only available to detect few pathogens and comes with a high false negative rate, relatively lower sensitivity (60-70%) and specificity (80-90%). In addition, standard antibody/antigen detection requires the infection to be present for days allowing the body to make ample antibodies in order to detect. Qualitative Nucleic Acid Amplification Testing (NAAT) is far superior with sensitivities and specificities > 98% and available to detect many pathogens. In addition, NAAT has built in controls to determine if an adequate patient sample was collected and processed, therefore greatly reducing false negative results. NAAT also includes controls to easily

Ordering Physician Signature

determine a contaminated sample, therefore reducing false positive results.

Date: